---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-22-001199"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:21:32.418386+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CVS Health authorizes $10B share repurchase program; amends bylaws for universal proxy rules

## Summary
- Board approved new $10B repurchase program after exhausting 2021 authorization.
- Repurchases may occur via open market, private deals, accelerated share repurchase, or derivatives.
- Bylaws amended to mandate compliance with SEC Rule 14a-19 for director nominations and proxies.

## SEC filing metadata
- accession: 0000947871-22-001199
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/0000947871-22-001199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/ss1535680_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-22-001199
- JSON: https://secwatch.observer/filing/0000947871-22-001199.json
- Plain text: https://secwatch.observer/filing/0000947871-22-001199.txt

## Key facts
- Governance Changes
  CVS HEALTH Corp: Amended by-laws to revise Section 1.10 regarding director nominations and proxy solicitations, including compliance with Rule 14a-19, and incorporate ministerial, clarifying and conforming changes (effective 2022-11-17).
  - Change: bylaw amendment
  - Effective: 2022-11-17
  source text: On November 17, 2022, the Board of Directors of CVS Health Corporation (the “Company”) amended, effective immediately, the by-laws (the “By-laws”) of the Company to (a) revise Section 1.10 with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000094787122001199/0000947871-22-001199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.